This opportunity supports rigorous validation of transformative, multi-use platforms or technologies that can significantly accelerate and transform early detection, screening, diagnosis, treatment, control, behavior, prevention, or epidemiology of HLBS-related diseases. It aims to facilitate the transition of basic science discoveries into viable diagnostic and therapeutic candidates cleared for human testing, fostering translational researchers skilled in product development and entrepreneurship.
Eligible applicants include a wide range of U.S.-based organizations such as nonprofits, tribal organizations, public and private institutions of higher education, government entities, and small businesses. Specific eligibility details are provided in the announcement.
